You have probably heard the stories. A friend, a colleague, maybe a family member who lost noticeable weight on a weekly shot. The harder question comes later, when the pen goes away.
A small US pilot trial, published October 7, 2026, in Obesity Science & Practice, tested two kinds of structured support after people stopped a GLP-1 drug. Both appeared to cut the familiar weight rebound by about two-thirds compared with usual care.
The researchers at Tufts University and the University of Texas Southwestern Medical Center followed 39 adults for four months after they came off their medication. The team wanted to see whether a weight-management app or weekly prepared meals could blunt the rebound.
What the three groups actually did
One group received usual care only. A second used Noom, a behavioral weight-management app, and logged food and activity each day. The third was sent 10 nutrient-dense meals a week, designed by dietitians with reduced calories and lower saturated fat.
Also read: How eating kiwi every day may help you fall asleep faster and sleep longer
Over the four months, the usual-care group regained about 10.75 percent of body weight. The app group regained about 3.60 percent. The medically tailored meal group regained about 3.58 percent.
Put another way, both support groups gained back roughly a third of what the control group did.
The lead author, Kelseanna Hollis-Hansen of Tufts University, said patients need backup for the moment the drug stops.
Why rebound is the standard story after stopping
GLP-1 drugs such as semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, work partly by quieting hunger and slowing how fast the stomach empties. When the drug is stopped, hunger and appetite cues return. Weight tends to follow.
Also read: Lifting weights for one week may wake up your body's fat-burning switch
The pattern is well documented. In the STEP 1 trial extension, participants took semaglutide for 68 weeks and then stopped both the drug and the lifestyle program.
In the following year, they regained an average of 11.6 percentage points of lost body weight. That was about two-thirds of what they had lost on treatment.
The new pilot is small and short. The authors say larger and longer trials are needed before this kind of post-cessation plan can be called proven.
The headline percentages were based on statistical modeling, and the trial was designed partly to see whether people would stick with each kind of help.
Also read: How eating sardines every week can affect your heart and cholesterol
What this means for the roughly 1 in 9 Americans on a GLP-1
GLP-1 use has climbed sharply. According to Gallup, 11 percent of US adults said in 2026 that they currently take a GLP-1 medication for weight loss, up from 3 percent in 2024. Many will eventually stop, whether for cost, side effects, or supply.
Patients who have lost weight on a GLP-1 and are thinking about coming off may want to raise post-cessation support with their clinician before stopping.
Options that showed early signal in the pilot include behavioral weight-management apps and portion-controlled, dietitian-designed meals delivered weekly.
Also read: Overlooked Ozempic side effect revealed: Nearly 4 in 10 experience it
Also read: Is alkaline water actually better for you? Here's what the evidence says
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.